Cell cycle control and cancer

Indian Journal of Pediatrics

Volumn 65, Issue 6, 1998, Pages 805-814

  Wagner, Hans Peter ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Department of Pediatrics ^*  (Switzerland)

Author keywords

Cancer; Cell cycle; Checkpoints; Chromosomal aberrations; Regulator proteins

Indexed keywords

ONCOPROTEIN;

CELL CYCLE; CELL TRANSFORMATION; CHILD; CHROMOSOME ABERRATION; DNA REPAIR; DNA REPLICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PHYSIOLOGY; REGULATOR GENE; REVIEW; TUMOR SUPPRESSOR GENE;

CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHROMOSOME ABERRATIONS; DNA REPAIR; DNA REPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REGULATOR; GENES, TUMOR SUPPRESSOR; HUMANS; PROTO-ONCOGENE PROTEINS;

EID: 0032195190     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02831338     Document Type: Conference Paper

References (68)

1. Murray AW, Kirschner MW. Dominoes and clocks : the union of two views of the cell cycle. Science 1989; 247 : 614-621.
2. Nasmyth K. Viewpoint, putting the cell cycle in order. Science 1996; 274 : 1643-1645.
3. Hartwell LH, Weinert TA. Checkpoints : Controls that ensure the order of cell cycle events. Science 1989; 246 : 629-634.
4. Elledge SJ. Cell cycle checkpoints : preventing an identity crisis. Science 1996; 274 : 1664-1672.
5. Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246 : 603-608.
6. Aronson S. Growth factors and cancer. Science 1991; 254 : 1146-1153.
7. Fisher RP, Morgan DO. A novel cyclin associates with MO15/cdk7 to form a cdk-activating kinase. Cell 1994; 78 : 713-724.
8. Morgan DO. Principles of cdk regulation. Nature 1995; 374 : 374 : 131-134
9. Nigg EA. Cyclin dependent kinase 7 : at the crossroads of transcription, DNA repair and cell cycle control? Curr Opin Cell Biol 1996; 8 : 312-317.
10. Dynlacht BD. Regulation of transcription by proteins that control the cell cycle. Nature 1997; 389 : 149-152.
11. Sherr CJ. Cancer cell cycle. Science 1996; 274 : 1672-1677.
12. Jacks T, Weinberg RA. The expanding role of cell cycle regulators. Science 1998; 280 : 1035-1036.
13. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81 : 323-330.
14. Dyson N. pRB, p107. and the regulation of the E2F transcription factor. J Cell Sci (suppl) 1994; 18 : 81-87.
15. Stillmann B. Cell cycle control of DNA replication. Science 1996; 274 : 1659-1664.
16. Chong JPJ, Mahbubani HM, Khoo C-Y, Blow JJ. Purification of an MCM-containing complex as a component of the DNA replication licensing system. Nature 1995; 375 : 418-421.
17. King RW, Deshaies RJ, Peters J-M, Kirschner MW. How proteolysis drives the cell cycle. Science 1996; 274 : 1652-1659.
18. Sancar A. Mechanisms of DNA excision repair. Science 1994; 266 : 1954-1956.
19. Brown L, McCarthy N. A sense-abl response ? Nature 1997; 387 : 450-451.
20. Baskaran R, Wood LD, Whitaker LL et al. Ataxia telangiectasia mutant protein activates c-able tyrosine kinase in response to ionizing radiation. Nature 1997; 387 : 516-519.
21. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70 : 523-526.
22. Prives C, Manfredi JJ. The p53 tumor suppressor protein. Genes Dev 1993; 7 : 529-534.
23. Wyllie A. Apoptosis. Clues in the p53 murder mystery. Nature 1997; 389 : 237-238.
24. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389 : H 300-305.
25. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Amer 1996; 274 (2) : 80-85.
26. De Lange T. Telomeres and senescence : ending the debate. Science 1998; 279 : 334-335.
27. Bodnar AG, Quelette M, Frolkis M et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279 : 349-352.
28. Peter M, Nakagawa J, Doree M, Labbé JC, Nigg EA. In vitro disassembly of the nuclear lamina arid M phase-specific phosphorylation of lamins by cdc2 kinase. Cell 1990; 61 : 591-602.
29. Duke RC, Ojcius DM, Young JD-E. Cell suicide in health and disease. Sci Amer 1996; 274 (6) : 48-55.
30. Nagata S, Goldstein P. The fas death factor. Science 1995; 267 : 1449-1456.
31. Chinnaiyan AM, Chaudhary D, O'Rourke K, Koonin EV, Dixit VM. Role of CED-4 in the activation of CED-3. Nature 1997; 388 : 728-729.
32. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388 : 190-195.
33. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387 : 773-776.
34. Krontiris TG. Oncogenes. N Engl J Med 1995; 333 : 303-306.
35. Weinberg RA. Tumor suppressor genes. Science 1991; 254 : 1138-1146.
36. Rabbits TH. Chromosomal translocations in humna cancer. Nature 1994; 372 : 143-149.
37. Gu W, Cechova K, Tassi V, Della-Favera R. Opposite regulation of gene transcription and cell proliferation by c-myc and Max. Proc Natl Acad Sci 1993; 90 : 2935-2939.
38. Ayer D, Kretzner L, Eisenmann R. Mad, a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72 : 211-222.
39. Zervos A, Gyuris J, Brent R. Mxi, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993; 72 : 223-232.
40. Amati B, Brooks M, Levy N et al. Oncogenic activity of the c-myc protein requires dimerization with Max. Cell 1993; 72 : 233-245
41. Uckun FM, Sensel MG, Sun L et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91 : 735-746.
42. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-able oncogene products. Science 1990; 247 : 1079-1082.
43. Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90 : 4947-4952.
44. Tenen DG, Hromas R, Licht JD, Zhang D-E Transcription factors, normal myeloid development and leukemia. Blood 1997; 90 : 489-519.
45. Okuda T, Cai Z, Yang S et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal finitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998; 91 : 3134-3143.
46. Benedetti L, Levin AA, Scicchitano BM et al Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood 1997; 90 : 1175-1185.
47. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia : clinical features v and molecular pathogenesis. Blood 1996; 87 : 1211-1224.
48. Poirel H, Rack K, Delabesse E et al. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood 1996; 87 : 2496-2505.
49. Behm FG, Raimondi SC, Frestedt JL et al Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996; 87 : 2870-2877.
50. Kelly KM, Warner RB, Sorensen PHB, Xiong QB, Barr FG. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997; 15 : 1831-1836.
51. Delattre O, Zucman J, Melot T et al The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331 : 294-299.
52. Zoubek A, Dockhorn-Dwornizak B, Delattre O et al. Does expression of different EWS chimeric transcripts define clinically distinct risk gorups of Ewing tumor patients? J Clin Oncol 1996; 14 : 1245-1251.
53. Motokura T, Bloom T, Kim HG et al. A novel cyclin encoded by a bell-linked candidate oncogene. Nature 1991; 350 : 512-515.
54. Khatib ZA, Matsushime H, Valentine M, et al. Coamplification of the CDK4 gene with MDM2 and GL1 in human sarcomas. Cancer Res 1993; 53 : 5535-5541.
55. He J, Allen JR, Collins VP et al CDK4 amplification is an alternative mechanism to pi6 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54 : 5804-5807.
56. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases and cdk inhibitors in human cancer. Adv Cancer Res 1996; 68 : 67-108.
57. Wang TC, Cardiff RD, Zuckerberg L Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTY-cyclin D1 transgenic mice. Nature 1994; 369 : 669-671.
58. Sicinski P, Donaker IL, Parker SB et al. Cyclin D1 provides a link between development and oncogenes in the retina and breast. Cell 1995; 82 : 621-630.
59. White PS, Maris JM, Beltinger C et al A region of consistent deletion in neuroblastoma maps within 1p36.2-2.3 Proc Natl Acad Sci USA 1995; 92 : 5520-5524.
60. Tonini GP, Boni L Pession A. et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s; the Italian experience with 275 children. J Clin Oncol 1997; 15 : 85-93.
61. Sellers WR, Kaelin Jr WG. Role of the retinoblastorna protein in the pathogenesis of human cancer. J Clin Oncol 1997; 15 : 3301-3312.
62. Alani RM, Monger K. Human papilloma virus and associated malignancies. J Clin Oncl 1998; 16 : 330-337.
63. Liggett JR WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16 : 1197-1206.
64. Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8 : 15-21.
65. INK4a mutations. N Engl J Med 1994; 333 : 970-974.
66. Reznikoff CA, Yeager TR, Belair CD et al. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 1996; 56 : 2886-2890.
67. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancer. Science 1991; 253 : 49-53.
68. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 1318-1327.